News

NEW YORK-- Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) announced today the initiation of the second of two pivotal phase 3 clinical trials evaluating the efficacy and safety of two different plecanatide treatment doses (3.0 mg and 6.0 mg), taken as a tablet once-a-day, in patients with irritable bowel syndrome with constipation (IBS-C).

- First of Two Planned Phase 3 Clinical Trials of Paratek's Lead Antibiotic Candidate - Studies Designed to Support Submission for Approval in Two Indications: Acute Bacterial Skin and Skin Structure Infections and Community Acquired Bacterial Pneumonia BOSTON, June 23, 2015 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon tetracycline chemistry today announced the dosing of the first patient in its Phase 3 clinical trial of its lead drug candidate, omadacycline, for the treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI). This global Phase 3 study will assess the efficacy and safety of omadacycline compared with linezolid in ABSSSI.

TORONTO, ONTARIO – (Marketwired) – Cynapsus Therapeutics Inc. (NASDAQ: CYNA) (TSX: CTH) (the “Company” or “Cynapsus”) announced today that it has completed its previously announced underwritten public offering in the United States (the “Offering”) of 5,175,000 common shares at a price to the public of US$14.00 per share, for total gross proceeds of approximately US$72.5 million, including the exercise in full of the underwriters’ option to purchase additional common shares.

RAMSEY, N.J., June 22, 2015 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq:ADMA), a late-stage biopharmaceutical company developing specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, announced that it has entered into a loan and security agreement with Oxford Finance LLC for up to $21 million.

FDA Breakthrough Therapy Designation for AR101 oral immunotherapy of peanut-allergic children and adolescents follows positive Phase 2 study results BRISBANE, Calif., June 18, 2015 — Aimmune Therapeutics, Inc., a privately held biopharmaceutical company developing desensitization treatments for food allergies, announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation status to AR101, the company’s lead investigational product, for oral immunotherapy of peanut-allergic children and adolescents 4-17 years of age.

TORONTO, ONTARIO -- Cynapsus Therapeutics Inc. (TSX:CTH)(OTCQX:CYNAD) (the "Company" or "Cynapsus") announced today the pricing of its underwritten public offering in the United States of 4,500,000 common shares at a price to the public of US$14.00 per share, for total gross proceeds of approximately US$63.0 million. In connection with the offering, the Company has granted to the underwriters a 30-day option to purchase up to an additional 675,000 common shares at the public offering price, less the underwriting discount. The offering is expected to close on or about June 23, 2015, subject to customary closing conditions. The Company's common shares are currently, and will continue to be, listed on the Toronto Stock Exchange ("TSX") under the symbol "CTH," and trading of the common shares is expected to commence on the NASDAQ Global Market ("NASDAQ") under the symbol "CYNA" on June 18, 2015.

NEW YORK-- Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today announced positive top-line results from the first of two pivotal phase 3 clinical trials evaluating the efficacy and safety of two different plecanatide treatment doses (3.0 mg and 6.0 mg), taken as a tablet once-a-day, in 1,346 adult patients with chronic idiopathic constipation (CIC).

DURHAM, N.C., June 16, 2015 (GLOBE NEWSWIRE) -- Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today announced that the underwriters of its previously announced public offering have exercised in full their option to purchase an additional 566,250 shares of its common stock at the public offering price of $39.75 per share, less customary underwriting discounts and commissions. As a result, the total number of shares being sold in the offering is 4,341,250 shares. The closing of the sale of all the shares in the offering is expected to occur today. Chimerix anticipates using the net proceeds from the offering to fund its research and development efforts and for general corporate purposes, including working capital.

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- TransEnterix, Inc. (NYSE MKT: TRXC), a medical device company that is pioneering the use of robotics and flexible instruments to improve minimally invasive surgery, today announced the pricing of its underwritten public offering of 16,666,667 shares of its common stock at a public offering price of $3.00 per share for total gross proceeds of $50.0 million. TransEnterix has also granted the underwriters a 30-day option to purchase up to an additional 2,500,000 million shares of common stock.

DURHAM, N.C., June 10, 2015 (GLOBE NEWSWIRE) -- Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today announced the pricing of an underwritten public offering of 3,775,000 shares of its common stock at a price to the public of $39.75 per share. The gross proceeds to Chimerix from this offering, before deducting underwriting discounts and commissions and other offering expenses payable by Chimerix, are expected to be approximately $150 million. The offering is expected to close on or about June 16, 2015, subject to customary closing conditions. Chimerix anticipates using the net proceeds from the offering to fund its research and development efforts and for general corporate purposes, including working capital.